Navigation Links
Mylan Launches First Generic Version of Xopenex(R) Inhalation Solution (Concentrate), 0.25%
Date:9/1/2009

PITTSBURGH, Sept. 1 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched levalbuterol inhalation solution USP (Concentrate), 0.25%, (1.25 mg/0.5 mL). Mylan, which has already launched the product, will market this product with 180 days of exclusivity.

This product, which is indicated for the treatment or prevention of bronchospasm in patients over 6 years old with reversible obstructive airway disease, is the first generic version of Sepracor Inc.'s Xopenex(R) Inhalation Solution (Concentrate), 0.25%, to be approved by the U.S. Food and Drug Administration (FDA). According to IMS Health, Xopenex Inhalation Solution (Concentrate), 0.25% had total U.S. sales of approximately $18.3 million for the 12 months ending June 30, 2009.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generics and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; operates a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
2. Mylans Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
3. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
4. President Clinton and Mylan Chairman and CEO Robert J. Coury Announce New Agreement to Lower Price of Treatment for Patients with Drug-Resistant HIV in Developing Countries
5. Mylan Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Closing Bell
6. Mylan Announces Enhancements to Executive Management Team
7. Mylan Reports That the FDA Determined That All Accusations Were Unfounded
8. Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
9. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own ... others prefer to read it, and some people don't like it at all. FindaTopDoc ... what they found: , Erotic literature can give readers a taste of their deepest, ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently ... Talei has come up with a proprietary technique that he calls the AuraLyft ... have dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... 2017 , ... Georgia State University will host the First ... two-day conference is focused on advancing scientific knowledge about the aggressive triple negative ... racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” , Conference ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... MD ... Florida. This is MD Now’s 28th facility overall and marks the urgent care center's ... located one mile North of The Falls shopping mall. The new clinic offers a ...
(Date:6/23/2017)... ... 23, 2017 , ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ) ... Management Agency’s (FEMA) recent update of flood zones, more people than ever are ... was enacted to reflect the actual risk in flood zone areas during a ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
(Date:5/26/2017)...  In response to the opioid epidemic in ... working with Pfizer to make up to 1 million ... community health centers, free and charitable clinics, public health ... "Pfizer has a long-standing commitment to improving health outcomes ... through educational activities," said Caroline Roan , vice ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology: